Mehta BK, Singh KK, Banerjee S
Semaglutide and tirzepatide medications have changed the treatment for obesity and diabetes
Multi-agonists Targeting multiple pathways at once While GLP-1 receptors slow gastric emptying and increase satiety, other gut hormones like GIP (glucose-dependent insulinotropic polypeptide) and glucagon also influence energy balance
Treating preclinical findings as personal proof of efficacy is exactly the mistake this overview is written to avoid
This narrow margin between deficiency and excess necessitates careful monitoring of Se supplementation, especially in individuals who may be at risk of selenosis due to high dietary Se intake or excessive supplementation [77]
Researchers should choose KLOW when their protocol requires melanocortin anti-inflammatory signaling, NF-kappaB suppression, gut mucosal targeting through KPVs PepT1 transporter uptake, or a comparison arm against GLOW to isolate KPVs contribution to inflammatory resolution outcomes